TY - JOUR
T1 - Polymer-drug conjugates
T2 - Recent development in clinical oncology
AU - Li, Chun
AU - Wallace, Sidney
N1 - Funding Information:
This work was supported in part by the National Cancer Institute (R29 CA74819), the Department of Defense (BC960384), and the John S. Dunn Foundation. We thank Michael Worley for editing the manuscript.
PY - 2008/5/22
Y1 - 2008/5/22
N2 - Targeted drug delivery aims to increase the therapeutic index by making more drug molecules available at the diseased sites while reducing systemic drug exposure. In this update, we provide an overview of polymer-drug conjugates that have advanced into clinical trials. These systems use synthetic water-soluble polymers as the drug carriers. The preclinical pharmacology and recent data in clinical trials with poly(l-glutamic acid)-paclitaxel (PG-TXL) are discussed. This is followed by a summary of a variety of polymeric conjugates with chemotherapeutic agents. Results from early clinical trials of these polymer-drug conjugates have demonstrated several advantages over the corresponding parent drugs, including fewer side effects, enhanced therapeutic efficacy, ease of drug administration, and improved patient compliance. Collectively, these data warrant further clinical development of polymer-drug conjugates as a new class of anticancer agents.
AB - Targeted drug delivery aims to increase the therapeutic index by making more drug molecules available at the diseased sites while reducing systemic drug exposure. In this update, we provide an overview of polymer-drug conjugates that have advanced into clinical trials. These systems use synthetic water-soluble polymers as the drug carriers. The preclinical pharmacology and recent data in clinical trials with poly(l-glutamic acid)-paclitaxel (PG-TXL) are discussed. This is followed by a summary of a variety of polymeric conjugates with chemotherapeutic agents. Results from early clinical trials of these polymer-drug conjugates have demonstrated several advantages over the corresponding parent drugs, including fewer side effects, enhanced therapeutic efficacy, ease of drug administration, and improved patient compliance. Collectively, these data warrant further clinical development of polymer-drug conjugates as a new class of anticancer agents.
KW - Anticancer drugs
KW - Nanocarriers
KW - PG-TXL
KW - Paclitaxel
KW - Polymer-drug conjugates
UR - http://www.scopus.com/inward/record.url?scp=42749091133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42749091133&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2007.11.009
DO - 10.1016/j.addr.2007.11.009
M3 - Review article
C2 - 18374448
AN - SCOPUS:42749091133
SN - 0169-409X
VL - 60
SP - 886
EP - 898
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
IS - 8
ER -